GSK Phase III COMPARZ study meets primary endpoint
The pazopanib demonstrated non-inferiority to sunitinib in terms of progression free survival (PFS) in the head-to-head study. GSK Oncology president Paolo Paoletti said, "There has been limited information
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.